petromyzonol sulfate: bile alocohol derivative that serves as a chemoattractant during the life cycle of sea lamprey (Petromyzon marinus) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
ID Source | ID |
---|---|
PubMed CID | 5200193 |
CHEBI ID | 50109 |
SCHEMBL ID | 13760030 |
MeSH ID | M0484547 |
Synonym |
---|
3alpha,7alpha,12alpha-trihydroxy-5alpha-cholan-24-yl hydrogen sulfate |
3alpha,7alpha,12alpha-trihydroxy-5alpha-cholan-24-yl sulfate |
CHEBI:50109 |
5alpha-cholan-3alpha,7alpha,12alpha-triol 24-sulfate |
petromyzonol 24-sulfate |
LMST05020018 |
[(4r)-4-[(3r,5r,7r,8r,9s,10s,12s,13r,14s,17r)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentyl] hydrogen sulfate |
petromyzonol sulfate |
20311-93-7 |
3n46rr2q4e , |
cholane-3,7,12,24-tetrol, 24-(hydrogen sulfate), (3alpha,5alpha,7alpha,12alpha)- |
5beta-petromyzonol sulfate |
unii-3n46rr2q4e |
SCHEMBL13760030 |
cholane-3,7,12,24-tetrol, 24-(hydrogen sulfate), (3.alpha.,5.alpha.,7.alpha.,12.alpha.)- |
DTXSID70897722 |
Q27121911 |
Class | Description |
---|---|
steroid sulfate | A sulfuric ester obtained by the formal condensation of a hydroxy group of any steroid with sulfuric acid. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 5 (26.32) | 29.6817 |
2010's | 12 (63.16) | 24.3611 |
2020's | 2 (10.53) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.77) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 1 (5.26%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 18 (94.74%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |